Zacks Investment Research upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning.
According to Zacks, “Alnylam reported positive data from the ATLAS study which led to regulatory filings for its late-stage pipeline candidate patisiran and an action date of Aug 11, 2018 as set by the FDA. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020. Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company. Stiff competition remains a threat as well. Estimates have remained stable ahead of the Q1 earnings results.”
Other analysts also recently issued research reports about the stock. B. Riley decreased their price target on shares of Alnylam Pharmaceuticals from $205.00 to $200.00 and set a buy rating for the company in a research note on Friday, February 16th. BidaskClub raised shares of Alnylam Pharmaceuticals from a hold rating to a buy rating in a research note on Wednesday, March 14th. Chardan Capital reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a research note on Friday, January 19th. Piper Jaffray reaffirmed a buy rating and set a $182.00 price target on shares of Alnylam Pharmaceuticals in a research note on Sunday, January 7th. Finally, Credit Suisse Group set a $151.00 price target on shares of Alnylam Pharmaceuticals and gave the company a buy rating in a research note on Friday, February 9th. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $134.15.
Shares of NASDAQ:ALNY opened at $96.19 on Tuesday. Alnylam Pharmaceuticals has a 1 year low of $49.19 and a 1 year high of $153.99. The company has a market cap of $9,786.75, a price-to-earnings ratio of -17.75 and a beta of 2.68. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.02.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The business had revenue of $37.90 million for the quarter, compared to analysts’ expectations of $19.31 million. During the same quarter last year, the firm earned ($1.32) EPS. The firm’s quarterly revenue was up 116.6% on a year-over-year basis. analysts anticipate that Alnylam Pharmaceuticals will post -7.02 EPS for the current fiscal year.
In other news, Director Philip A. Sharp sold 15,000 shares of the company’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $129.00, for a total transaction of $1,935,000.00. Following the transaction, the director now directly owns 155,795 shares of the company’s stock, valued at $20,097,555. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Yvonne Greenstreet sold 7,221 shares of the company’s stock in a transaction on Monday, March 26th. The stock was sold at an average price of $136.54, for a total value of $985,955.34. Following the transaction, the chief operating officer now directly owns 7,221 shares in the company, valued at $985,955.34. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 198,620 shares of company stock worth $28,404,143. Insiders own 4.30% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Strs Ohio acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $141,000. CENTRAL TRUST Co increased its position in shares of Alnylam Pharmaceuticals by 746.3% during the fourth quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 1,000 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $165,000. American International Group Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $255,000. Finally, Vident Investment Advisory LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $262,000. 92.00% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Alnylam Pharmaceuticals (ALNY) Lifted to Hold at Zacks Investment Research” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.thelincolnianonline.com/2018/04/20/alnylam-pharmaceuticals-alny-lifted-to-hold-at-zacks-investment-research.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.